drugset
drugset / Trial / NCT06074705

A Study of DS-1471a In Subjects With Advanced Solid Tumors

NCT06074705 ↗

Phase 1 Terminated 17 enrolled Daiichi Sankyo
Non-randomizedSequentialOpen-labelTreatment

Summary

This first-in-human (FIH) study will assess the safety, preliminary efficacy, pharmacokinetics (PK), and immunogenicity of DS-1471a in participants with advanced or metastatic solid tumors.

Timeline

Start
2023-08-04
Primary completion
2025-07-29
Completion
2025-07-29

Outcome

Outcome not reported

Stopped (Business): “The study was terminated by the sponsor due to a business decision.”

Drugs

EvaluationDrugModalityDoseRoute
Subject DS-1471a Unknown — Intravenous

Indications

neoplasm